Table 2.
MGFA clinical classification at onset and at maximal worsening is shown for drug‐refractory myasthenia gravis patients according to immunological subgroup.
| AChR MG | MuSK MG | AChR + MuSK MG | Seronegative MG | |
|---|---|---|---|---|
| MGFA at onset | n = 65 | n = 5 | n = 1 | n = 9 |
| I | 14 | 0 | 0 | 4 |
| IIA | 12 | 0 | 0 | 3 |
| IIB | 12 | 2 | 0 | 0 |
| IIIA | 4 | 1 | 0 | 1 |
| IIIB | 11 | 1 | 0 | 1 |
| IVA | 3 | 0 | 0 | 0 |
| IVB | 7 | 1 | 0 | 0 |
| V | 2 | 0 | 1 | 0 |
| MGFA at maximal worsening | n = 62 | n = 5 | n = 1 | n = 10 |
| I | 4 | 0 | 0 | 2 |
| IIA | 4 | 0 | 0 | 3 |
| IIB | 4 | 1 | 0 | 1 |
| IIIA | 6 | 0 | 0 | 3 |
| IIIB | 19 | 2 | 0 | 0 |
| IVA | 6 | 0 | 0 | 1 |
| IVB | 12 | 1 | 0 | 0 |
| V | 7 | 1 | 1 | 0 |
MG, myasthenia gravis; MGFA, Myasthenia Gravis Foundation of America; AChR, acetylcholine receptor; MuSK, muscle‐specific tyrosine kinase.